Comparing Efficacy & Safety Of TNX-1300 To Placebo With UC For Treatment Of Acute Cocaine Intoxication In ED Subjects (CATALYST)

PHASE2

Phase

TERMINATED

Status

Enrollment

INDUSTRY

Sponsor class

Stopped Tonix has discontinued enrollment and terminated the Phase 2 CATALYST study (TNX-CE-CI202) because enrollment in this emergency department-based study was slower than projected. The study was not discontinued for safety or efficacy reasons.

Conditions

Cocaine Use
Cocaine Intoxication
Cocaine Toxicity
Cocaine Abuse
Cocaine Adverse Reaction

Interventions

DRUG: TNX-1300 (Injection)
DRUG: Placebo (Injection)

Sponsor

Tonix Pharmaceuticals, Inc.

Collaborators

[object Object]
[object Object]